Caution in Use – Trazodone Hydrochloride

15th August 2024

Dear Customer

Dawa Limited has issued a Class 4 Medicines Defect Information –  Caution in Use. In relation to:

Trazodone Hydrochloride 50mg Capsules, PL 30684/0250
Trazodone Hydrochloride 100mg Capsules, PL 30684/0251
Trazodone Hydrochloride 50mg/5ml Oral Solution, PL 30684/0268

 Brief description of the problem

Dawa Limited has informed the MHRA of an error with the Patient Information Leaflets (PILs) that have been packed in the listed batches of Trazodone Hydrochloride 50mg and 100mg Capsules and Trazodone Hydrochloride 50mg/5ml Oral Solution.

The PIL does not contain the latest safety information relating to serotonergic products (trazodone) and the interaction with buprenorphine.

The following details the affected products & batches that have been stocked, sold & continue to be sold by NVS

NVS Product Code(s) Product Description Affected Batch No’s Expiry Date Stock Position
563006 Trazodone Caps 50mg, PK 84 220191 Apr-26 Sold Through
220192 Apr-26 Sold Through
220193 Apr-26 Currently Selling
220212 Apr-26 Sold Through
220340 Jun-26 Sold Through
220382 Jul-26 Sold Through

 

NVS Product Code(s) Product Description Affected Batch No’s Expiry Date Stock Position
578101 Trazodone Caps 100mg, PK 56 200284 Sept-24 Sold Through
220213 May-26 Sold Through
220215 May-26 Sold Through
220341 Jun-26 Currently Selling


Advice for healthcare professionals

There is no risk to product quality because of this issue, therefore the affected batches are not being recalled. Healthcare professionals are advised to exercise caution when dispensing the products and where possible, provide an updated PIL.

What to do next – Please read the attached notification letter (Please click here) and bring the issue to the attention of all relevant colleagues within your business. The updated PIL is available electronically and can be downloaded from the links within the notification letter: